Prevention and management of thrombosis in myeloproliferative neoplasms.
Authors: Sekhar M PMID: 28398271 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - April 13, 2017 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Prognostic and predictive biomarkers in metastatic castration-resistant prostate cancer.
Authors: Armstrong AJ PMID: 28398272 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - April 13, 2017 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

The use of immunotherapy in the first-line treatment of lung cancer.
Authors: Rizvi NA PMID: 28398273 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - April 13, 2017 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

The new NCCN guidelines for the management of myelofibrosis.
Authors: Mesa RA PMID: 28398274 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - April 13, 2017 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Natural killer/T-cell lymphomas in pediatric and adolescent patients.
Authors: Termuhlen AM Abstract Natural killer/T-cell (NK/T-cell) lymphomas are rare in children and adolescents and consist predominantly of nasal-type extranodal NK/T-cell lymphomas. More than half of pediatric/adolescent patients with NK/T-cell lymphomas present with localized nasal/sinus involvement, but the disease may involve many organs. NK/T-cell lymphoma cells are cytotoxic and associated with necrosis and angioinvasion; they express CD56, CD2, cytoplasmic CD3 epsilon, and to a variable degree CD30. The cells contain Epstein-Barr virus (EBV)-encoded RNA. Loss of chromosome 6q is frequent, and multiple other...
Source: Clinical Advances in Hematology and Oncology - April 13, 2017 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

BCL-2 as a therapeutic target in chronic lymphocytic leukemia.
Authors: Daniel C, Mato AR Abstract Venetoclax (formerly ABT-199) was recently approved in the United States for the treatment of patients who have relapsed or refractory chronic lymphocytic leukemia (CLL) with the 17p deletion. Venetoclax has demonstrated marked activity as monotherapy as well as in combination with cytotoxic chemotherapies, B-cell receptor inhibitors, and anti-CD20 monoclonal antibodies across the spectrum of CLL. The potency of venetoclax has been associated with a unique ability to induce deep (minimal residual disease-negative) complete remissions that appear to be durable. Its toxicity profil...
Source: Clinical Advances in Hematology and Oncology - April 13, 2017 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Letter From the Editor: Inauguration week.
Authors: Kahl BS PMID: 28398277 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - April 13, 2017 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Barriers to the development of drugs for primary brain tumors.
Authors: Chang SM PMID: 28398278 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - April 13, 2017 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Is there a role for single-agent BRAF inhibition in melanoma?
Authors: Chmielowski B PMID: 28398279 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - April 13, 2017 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Highlights in gene therapy and alternative therapies in nonmalignant hematology from the 2016 American Society of Hematology meeting.
Authors: PMID: 28398280 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - April 13, 2017 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

An interim analysis of the ZUMA-1 study of KTE-C19 in refractory, aggressive non-Hodgkin lymphoma.
Authors: Neelapu SS PMID: 28398281 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - April 13, 2017 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

The role of regorafenib in hepatocellular carcinoma.
Authors: Frenette CT PMID: 28398282 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - April 13, 2017 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

The future of immunotherapy as perioperative therapy in renal cell carcinoma.
Authors: PMID: 28398283 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - April 13, 2017 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Manifestations and management of veno-occlusive disease/sinusoidal obstruction syndrome in the era of contemporary therapies.
Authors: Tewari P, Wallis W, Kebriaei P Abstract The concept of veno-occlusive disease (VOD), along with our understanding of it, has historically been and remains an evolving phenomenon. This review presents a broad view of VOD, also known as sinusoidal obstruction syndrome (SOS), including (1) traditional hematopoietic stem cell transplant-associated VOD/SOS, (2) late-onset VOD/SOS, (3) pulmonary VOD, and (4) VOD/SOS associated with chemotherapy only. Several VOD/SOS management modalities exist that include modes for both prophylaxis and treatment. An extensive review of the literature on monoclonal antibodies, b...
Source: Clinical Advances in Hematology and Oncology - April 13, 2017 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Evolving standards of care for resected pancreatic cancer.
Authors: Weinberg BA, Philip PA, Salem ME Abstract Pancreatic cancer is a devastating illness, and surgical resection offers the only chance of a cure for patients with the disease. Relatively few patients have resectable disease at diagnosis, however, and the cancer frequently recurs even after complete surgical resection. This review discusses clinical trials in which adjuvant therapy with chemotherapy or chemoradiation has prolonged survival in patients following surgery. It also highlights new data from the ESPAC-4 and JASPAC 01 studies that may change the current treatment paradigm for adjuvant therapy. The ES...
Source: Clinical Advances in Hematology and Oncology - April 13, 2017 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Letter From the Editor: The end.
Authors: Cheson BD PMID: 28212355 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - February 19, 2017 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

The seamless approach to drug development in oncology.
Authors: Pazdur R PMID: 28212356 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - February 19, 2017 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Is precision medicine ready for use in breast cancer?
Authors: Pusztai L PMID: 28212357 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - February 19, 2017 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Kidney cancer news.
Authors: PMID: 28212358 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - February 19, 2017 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Considerations in the frontline treatment of chronic lymphocytic leukemia.
Authors: O'Brien SM PMID: 28212359 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - February 19, 2017 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Is there a role for single-agent MEK inhibition in melanoma?
Authors: Johnson D PMID: 28212360 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - February 19, 2017 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Liver transplant and hepatocellular carcinoma.
Authors: Wong R PMID: 28212361 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - February 19, 2017 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

The management of psychological issues in oncology.
Authors: McFarland DC, Holland JC Abstract Psychological issues in the cancer setting are highly prevalent and well documented, and can lead to adverse outcomes. Several series of guidelines have been put forth to ensure that both psychological and psychiatric issues are addressed. The management of psychological issues in cancer is relevant for clinicians whose patients are identified clinically or via screening mechanisms with psychological or psychiatric sequelae from cancer. This review describes the psychological impact of cancer, distress screening as a triage mechanism, and the presentation and management of...
Source: Clinical Advances in Hematology and Oncology - February 19, 2017 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

VEGF inhibitors in renal cell carcinoma.
Authors: Vachhani P, George S Abstract The arrival of targeted therapies-vascular endothelial growth factor (VEGF) pathway inhibitors and mammalian target of rapamycin (mTOR) inhibitors-and programmed death 1 (PD-1) inhibitors has transformed the management of renal cell carcinoma (RCC). Once considered fatal, with a median survival of approximately 1 year, these agents have nearly tripled overall survival and have raised hopes of a possible cure for advanced RCC. This review begins with a brief discussion of the seminal von Hippel-Lindau/hypoxia-inducible factor axis in RCC. It then discusses the pivotal trials th...
Source: Clinical Advances in Hematology and Oncology - February 19, 2017 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Letter From the Editor: The ASH rehash.
Authors: Kahl BS PMID: 28212364 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - February 19, 2017 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Right-sided vs left-sided colorectal cancer.
Authors: Venook AP PMID: 28212365 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - February 19, 2017 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Challenges in drug development for children.
Authors: Adamson PC PMID: 28212366 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - February 19, 2017 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Superficial vein thrombosis: new perspectives and observations from recent clinical trials.
Authors: Cosmi B PMID: 28212367 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - February 19, 2017 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Aggressive B-cell lymphoma: the double-hit and double-expressor phenotypes.
Authors: Smith SM PMID: 28212368 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - February 19, 2017 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Prognostic biomarkers in early-stage prostate cancer.
Authors: Klein E PMID: 28212369 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - February 19, 2017 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

The evolution of allogeneic stem cell transplant for children and adolescents with acute myeloid leukemia.
Authors: Flower A, Cairo MS Abstract Survival rates in subsets of pediatric patients who have acute myeloid leukemia (AML) with favorable risk features are now greater than 90%. However, outcomes for patients with high-risk (HR) features remain unacceptably poor. As novel technologies for the identification of HR biomarkers and the detection of residual disease are developed, risk stratification and the application of allogeneic hematopoietic stem cell transplant (HSCT) are evolving. HSCT has been shown to benefit subpopulations of pediatric patients with AML, including those with HR cytogenetic translocations, gen...
Source: Clinical Advances in Hematology and Oncology - February 19, 2017 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Circulating tumor cells in prostate cancer: beyond enumeration.
Authors: Chen JF, Lu YT, Cheng S, Tseng HR, Figlin RA, Posadas EM Abstract Circulating tumor cells (CTCs) are a population of rare cancer cells that have detached from the primary tumor and/or metastatic lesions and entered the peripheral circulation. Enumeration of CTCs has demonstrated value as a prognostic biomarker, and newer studies have pointed to information beyond enumeration that is of critical importance in prostate cancer. Technologic advances that permit examination of the morphology, function, and molecular content of CTCs have made it possible to measure these factors as part of liquid biopsy. These a...
Source: Clinical Advances in Hematology and Oncology - February 19, 2017 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Molecular biology of gastroesophageal cancers: opportunities and challenges.
Authors: Khan S, Mikhail S, Xiu J, Salem ME Abstract Gastroesophageal (GE) malignancies make up a significant and growing segment of newly diagnosed cancers. Approximately 80% of patients who have GE cancers die within 5 years of diagnosis, which means that effective treatments for these malignancies need to be found. Currently, targeted therapies have a minimal role in this disease group. Intensive study of the molecular biology of GE cancers is a relatively new and ongoing venture, but it has already led to a significant increase in our understanding of these malignancies. This understanding, although still limit...
Source: Clinical Advances in Hematology and Oncology - February 19, 2017 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Second-line therapy for patients with hepatocellular carcinoma.
Authors: Frenette CT PMID: 27930616 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - December 9, 2016 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Preserving the liver for second-line treatment of hepatocellular carcinoma.
Authors: Lencioni R PMID: 27930617 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - December 9, 2016 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Developing a treatment plan for hepatocellular carcinoma: the continuum of care.
Authors: Finn RS PMID: 27930618 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - December 9, 2016 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Novel second-line treatments for hepatocellular carcinoma: Discussion.
Discussion. Clin Adv Hematol Oncol. 2016 Dec;14 Suppl 12(12):12-13 Authors: Frenette CT, Lencioni R, Finn RS PMID: 27930619 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - December 9, 2016 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Atypical hemolytic uremic syndrome (aHUS): essential aspects of an accurate diagnosis.
Authors: Laurence J, Haller H, Mannucci PM, Nangaku M, Praga M, Rodriguez de Cordoba S Abstract Atypical hemolytic uremic syndrome (aHUS), a thrombotic microangiopathy (TMA), is a rare, life-threatening, systemic disease. When unrecognized or inappropriately treated, aHUS has a high degree of morbidity and mortality. aHUS results from chronic, uncontrolled activity of the alternative complement pathway, which activates platelets and damages the endothelium. Two-thirds of aHUS cases are associated with an identifiable complement-activating condition. aHUS is clinically very similar to the other major TMAs: Shiga tox...
Source: Clinical Advances in Hematology and Oncology - December 9, 2016 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Highlights in CINV from the 2016 MASCC/ISOO annual meeting.
Authors: PMID: 27930621 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - December 9, 2016 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Highlights in CINV from the 2016 MASCC/ISOO annual meeting: Commentary.
Authors: Schwartzberg LS PMID: 27930622 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - December 9, 2016 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Letter From the Editor: Fellowship interviews and more.
Authors: Cheson BD PMID: 27930623 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - December 9, 2016 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Kidney Cancer News.
Authors: PMID: 27930624 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - December 9, 2016 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

The evolving role of chemoimmunotherapy in chronic lymphocytic leukemia.
Authors: Lamanna N PMID: 27930625 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - December 9, 2016 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

The role of liver biopsy in hepatocellular carcinoma.
Authors: Finn RS PMID: 27930626 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - December 9, 2016 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Update on the treatment of uveal melanoma.
Authors: Carvajal RD PMID: 27930627 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - December 9, 2016 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Should we consider adjuvant therapy for rectal cancer after neoadjuvant chemoradiotherapy?
Authors: Benson AB PMID: 27930628 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - December 9, 2016 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

The I-SPY approach to drug development.
Authors: Esserman L PMID: 27930629 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - December 9, 2016 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Obesity and breast cancer: risk, outcomes, and future considerations.
Authors: Yung RL, Ligibel JA Abstract The proportion of adults who are obese has increased dramatically in the United States over the last 30 years. Obesity has been linked to an increased risk of developing a number of malignancies, including postmenopausal breast cancer. Evidence also suggests that obesity at the time of breast cancer diagnosis is linked to an increased risk of breast cancer-specific and overall mortality in both premenopausal and postmenopausal women with early-stage breast cancer. Obesity is linked to an increased risk of secondary malignancies in women with early breast cancer, and studies sug...
Source: Clinical Advances in Hematology and Oncology - December 9, 2016 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

CD19-Targeted CAR T cells as novel cancer immunotherapy for relapsed or refractory B-cell acute lymphoblastic leukemia.
Authors: Davila ML, Brentjens RJ Abstract Immunotherapy has demonstrated significant potential for the treatment of patients with chemotherapy-resistant hematologic malignancies and solid tumors. One type of immunotherapy involves the adoptive transfer of T cells that have been genetically modified with a chimeric antigen receptor (CAR) to target a tumor. These hybrid proteins are composed of the antigen-binding domains of an antibody fused to T-cell receptor signaling machinery. CAR T cells that target CD19 recently have made the jump from the laboratory to the clinic, and the results have been remarkable. CD19-ta...
Source: Clinical Advances in Hematology and Oncology - December 9, 2016 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Highlights in polycythemia vera from the 2016 EHA congress.
Authors: Verstovsek S Abstract Meeting highlights from the European Hematology Association congress, June 9-12, Copenhagen, Denmark. PMID: 27930632 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - December 9, 2016 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research